Breaking News

Tubal ligations and vasectomies shot up post-Dobbs

April 15, 2024
theresa-g-avatar-small - light bg
Morning Rounds Writer and Podcast Producer

Good morning! Send speedy thoughts to STAT's Liz Cooney, who's running her 14th Boston Marathon today!

Also, please consider taking this quick, easy survey on our newsletters. Think of it as a favor to me on my first day as the lead Morning Rounds writer. (If you missed this news last week, scroll down to the last item for more on me, my hair, and this newsletter!)

biotech

Vir pivots away from its once-treasured focus on infectious disease

April15-mikeReddy

Mike Reddy for STAT

Nearly a decade ago, venture capitalist Bob Nelsen called industry veteran Vicki Sato to pitch her on launching a large company dedicated to tackling the world's worst pathogens. Sato said it was a crazy idea — all the big companies had moved on to more profitable targets like cancer and neurology. Still, she was on board.

They formed Vir Biotechnology, raising near-record-breaking amounts of money. When Covid hit, it took 10 months for Vir to create a drug that likely saved hundreds, if not thousands, of lives, and definitely made billions of dollars. The company was a test case of whether investing in infectious disease could be profitable, STAT's Jason Mast writes. But despite its success, the company has made sweeping changes over the past year that suggest its future may lie elsewhere.

"Taking on infectious disease as a corporate mandate is challenging in these times, even though the real medical need in infectious disease is tremendous and I for one have not lost my passion," said Sato, who still serves as chairwoman, though nearly the entire C-suite has been replaced. Read more from Jason on the changes at Vir and what they mean.


reproductive health

Before and after Dobbs: Permanent contraception procedures

CHART-CONTRACEPTION

JAMA Health Forum

The number of people getting permanent contraception procedures — tubal ligations and vasectomies — increased abruptly in the summer of 2022 when the Supreme Court overturned the constitutional right to an abortion, according to a new study in JAMA Health Forum. Researchers used electronic health records from patients ages 18-30 to calculate the changes. They found that the increase in tubal ligations was double the increase seen in vasectomies. 

This difference is particularly striking when considering the fact that getting one's tubes tied can cost almost five times as much as a vasectomy. It's also a more invasive, painful procedure — though, like in so many areas of women's reproductive health, research on the experience is scarce


the war on recovery

More than 1 in 4 younger Canadian deaths were opioid-related in 2021

The number of premature deaths associated with opioids across much of Canada doubled between 2019 and 2021, according to a new study in the Canadian Medical Association Journal. In 2021, that meant 1 in 4 deaths among those aged 20-39 were related to opioids. Similarly, opioids accounted for 1.7% of all deaths among people younger than 85 in 2019, but that figure rose to 3.2% in 2021. To identify these trends, researchers analyzed data on accidental opioid-related deaths from nine out of 13 provinces and territories in the country.

As stark as these numbers are, STAT's addiction reporter Lev Facher reminded me that the problem is actually so much worse here in the U.S. There were more than 6,000 opioid-related deaths in Canada in 2021, per this study. Here, more than 80,000 people die from an opioid overdose each year.

Lev is currently reporting an extensive series about how the U.S. is severely underutilizing our best tools to combat the opioid epidemic. "They're making it easier for me to relapse, in a way, because of some of the rules they're trying to throw at you," one person who has struggled to keep access to methadone told him. If you haven't read the first few stories from The War on Recovery yet, I urge you to do so.



opinion

Girls can get ADHD, too, and they need treatment

MRAPRIL15-1

Adobe

Overactive, disruptive boys who need help to focus on their schoolwork have long been a sort of cultural poster child for ADHD, or attention-deficit/hyperactivity disorder. But in a new First Opinion, psychiatrist Michael Morse and psychologist Kathleen Nadau point to an important fact: Women and girls can also have ADHD, and when they do, they're chronically underdiagnosed and undertreated.

Part of the problem may lie in the diagnostic criteria for ADHD. "The current criteria are not fine-tuned to identify more subtle presentations of ADHD in females," they write. Additionally, girls are often less likely to be disruptive at school or at home than boys. "But the fact that females with ADHD may not be a problem for others doesn't mean that they are not suffering in silence," they add. Read more on how this gender disparity came to be, and why there is hope on the horizon to change it. 


hospitals

Q&A: Mass General Brigham CEO says they're ready to move on without Dana-Farber

The split between Dana-Farber Cancer Institute and Mass General Brigham has been messy. After catching MGB CEO Anne Klibanski on the sidelines of a conference in Chicago last week, STAT's Bob Herman spoke with her about the fallout:

What's the latest on the relationship with Dana-Farber Cancer Institute? The current relationship between you and Dana-Farber lasts until 2028. Has the ship fully sailed?

Yes, we are contractually obligated to go ahead, as we are planning to do. And at the same time, as we continue to provide that care, we also are developing what Mass General Brigham cancer [care] would look like.

So it sounds like there's no love lost here?

There are clinical and research care teams that have worked together for decades. The announcement came out from the Farber. This was a Farber business decision to build their own medical oncology hospital. That was their announcement. The people, the relationships, the care — that's gone on for decades. So all the caregivers, physicians, and researchers were stunned by this announcement.

Read more.


introductions

Hello!

The inimitable Liz Cooney wrote her last issue as this newsletter's lead writer last week, as she moves on to cover the cardiovascular beat at STAT. You know as well as I do how wonderful it's been to read her dispatches every morning for the last few years. But I'll tell you that it's been even more of a pleasure to work with her on the team for the past few months. She's left big, marathon-running shoes to fill. And while I will absolutely not be running a marathon anytime soon, I am very excited to start bringing the most important health news to your inbox every morning. 

And who am I, you might be asking? I started at STAT in the summer of 2020 as an intern, and essentially, haven't let them get rid of me since! (My headshot is from that frantic pandemic era when we were all cutting our own hair, hence the shaved head. How could I have known it would still be front and center on every byline all these years later?) The very first Morning Rounds writer, Megan Thielking, was my own first editor at STAT, helping me craft stories on topics like period poverty and the mental health crisis. Which reminds me: As I take on this new role, I'll still be reporting for STAT on new science, gender-affirming care, mental health, and more. Feel free to send any leads my way: theresa.gaffney@statnews.com

On logistics: You can still catch my colleague Annalisa Merelli here on Fridays. And seriously, please do take a minute to fill out our survey. It would be greatly appreciated!


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

In case you missed it:

  • European regulators find no evidence of link between new obesity medicines and suicidal thoughts, STAT

  • Texas surgeon is accused of secretly denying liver transplants, New York Times
  • When a cancer drug fails, oncologists often fly blind. A precision technique might light the way, STAT
  • Do 'griefbots' help mourners deal with loss? Undark

Thanks for reading! More tomorrow — Theresa


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments